C R Parish
Overview
Explore the profile of C R Parish including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
193
Citations
3311
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Gorgani N, Parish C, Altin J
J Biol Chem
. 1999 Oct;
274(42):29633-40.
PMID: 10514432
In previous studies we showed that the plasma protein histidine-rich glycoprotein (HRG) binds strongly to pooled human IgG. In the present work myeloma proteins consisting of different human IgG subclasses...
22.
Baker E, Crawford J, Sutherland G, Freeman C, Parish C, Hulett M
Chromosome Res
. 1999 Aug;
7(4):319.
PMID: 10461877
No abstract available.
23.
Freeman C, Browne A, Parish C
Biochem J
. 1999 Aug;
342 ( Pt 2):361-8.
PMID: 10455023
In order to enter tissues, blood-borne metastatic tumour cells and leucocytes need to extravasate through the vascular basal lamina (BL), a process which involves a battery of degradative enzymes. A...
24.
Histidine-rich glycoprotein regulates the binding of monomeric IgG and immune complexes to monocytes
Gorgani N, Altin J, Parish C
Int Immunol
. 1999 Jul;
11(8):1275-82.
PMID: 10421785
Histidine-rich glycoprotein (HRG) is a relatively abundant plasma protein which we have shown previously inhibits the formation of insoluble immune complexes (IC). In this study we examined the ability of...
25.
Parish C, Freeman C, Brown K, Francis D, Cowden W
Cancer Res
. 1999 Jul;
59(14):3433-41.
PMID: 10416607
Inhibitors of tumor angiogenesis and metastasis are rapidly emerging as important new drug candidates for cancer therapy. To facilitate the identification of such drugs, we recently developed novel and rapid...
26.
Hulett M, Freeman C, Hamdorf B, Baker R, Harris M, Parish C
Nat Med
. 1999 Jul;
5(7):803-9.
PMID: 10395326
The endoglycosidase heparanase is an important in the degradation of the extracellular matrix by invading cells, notably metastatic tumor cells and migrating leukocytes. Here we report the cDNA sequence of...
27.
Smith J, Hart P, Parish C, Standfield S, Coster D, Williams K
Clin Exp Immunol
. 1999 Feb;
115(1):64-71.
PMID: 9933421
Experimental melanin-induced uveitis (EMIU) is a rodent model of acute anterior uveitis which was described in 1993. We investigated strain susceptibility, and age and gender characteristics of the model, undertook...
28.
Vassiliou G, Jakobsen K, Parish C
J Immunol Methods
. 1998 Sep;
215(1-2):9-15.
PMID: 9744743
Cell-cell interactions involve highly polyvalent associations between receptors on adjacent cells. In order to mimic this process, we have prepared a highly polyvalent form of CD40 attached to a dextran...
29.
Freeman C, Parish C
Biochem J
. 1998 May;
330 ( Pt 3):1341-50.
PMID: 9494105
Heparan sulphate (HS) is an important component of the extracellular matrix (ECM) and the vasculature basal lamina (BL) which functions as a barrier to the extravasation of metastatic and inflammatory...
30.
Parish C, Hindmarsh E, Bartlett M, Staykova M, Cowden W, Willenborg D
Immunol Cell Biol
. 1998 Apr;
76(1):104-13.
PMID: 9553782
Currently available anti-inflammatory drugs for the treatment of multiple sclerosis (MS) and other inflammatory diseases are generally inadequate, with disease progression not being arrested by the treatments and undesirable side...